Physician profile

Magdy Selim

Vascular Neurology · Boston, MA

NPI 1245271881

$5,970.50

in general payments reported to CMS, 2019-2025

3 companies · $3,766 in 2025

The $3,766 reported for 2025 was more than what 86% of Vascular Neurology providers received nationally (typical 2025 total: $360).

See the full distribution for Vascular Neurology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$5,310.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $3,862.50 2024-2025
Csl Behring $1,448.00 2025 Kcentra
Alexion Pharmaceuticals, INC. $660.00 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Magdy Selim

$5,970.50

in general payments reported 2019-2025

Years
2020-2025
Top company
Alnylam Pharmaceuticals INC.
Context
The $3,766 reported for 2025 was more than what 86% of Vascular Neurology providers received nationally (typical 2025 total: $360).

https://glasscript.com/doctor/1195652/magdy-selim

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.